

## Claims

1. An oligonucleotide comprising an unmethylated CG dinucleotide (CpG) of the following sequence: 5'-*tccatgacgttcctgacgtt*-3' SEQ ID No. 1, attached to the following LNA sequence, optionally through one or more nucleotide linker residues:  
5'-GGAAGGAAGGAAGG-3' , SEQ ID No. 2.
2. An oligonucleotide as claimed in claim 1 wherein the sequence is selected from SEQ ID NO. 3, SEQ ID NO. 14, SEQ ID NO. 18 or SEQ ID NO. 20.
3. A complex comprising a plasmid and attached thereto a plurality of oligonucleotides as claimed in claim 1 or claim 2.
4. A method of manufacturing a LNA – CpG conjugate comprising co-synthesising the entire sequence.
5. A method of manufacturing a LNA-CpG conjugate as claimed in claim 4, wherein the sequence of the LNA-CpG conjugate has sufficiently low predicted self annealing and secondary structure forming capacity to prevent inhibition of binding to a plasmid or CpG adjuvant activity.